Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Non-Current Debt (2016 - 2026)

Apyx Medical filings provide 13 years of Non-Current Debt readings, the most recent being $34.8 million for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 2.82% to $34.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.8 million, a 2.82% increase, with the full-year FY2025 number at $34.8 million, up 2.82% from a year prior.
  • Non-Current Debt hit $34.8 million in Q4 2025 for Apyx Medical, up from $34.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $34.8 million in Q4 2025 to a low of $9.0 million in Q3 2023.
  • Median Non-Current Debt over the past 3 years was $33.9 million (2024), compared with a mean of $31.5 million.
  • The widest YoY moves for Non-Current Debt: up 275.77% in 2024, down 2.13% in 2024.
  • Apyx Medical's Non-Current Debt stood at $33.2 million in 2023, then grew by 2.13% to $33.9 million in 2024, then grew by 2.82% to $34.8 million in 2025.
  • The last three reported values for Non-Current Debt were $34.8 million (Q4 2025), $34.6 million (Q3 2025), and $34.4 million (Q2 2025) per Business Quant data.